Referring to the bulletin from Mendus AB's annual general meeting, held on May 17, 2024, the company will carry out a reverse stock split in relations 1:20. The share will be traded under new ISIN code with effect from Jun 3, 2024. The order book will not change. Short name: IMMU Terms: Reverse split: 1:20 Current ISIN: SE0005003654 Last day of trading with current ISIN code: May 31, 2024 New ISIN code: SE0022239950 First day of trading with new ISIN code: Jun 3, 2024
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Mendus - Vididencel shines in ALISON trial (ovarian cancer) | Mendus has reported positive top-line data for its Phase I ALISON trial, which is evaluating lead off-the-shelf cancer vaccine, vididencel, in high-grade serous ovarian carcinoma (HGSC). The news corresponds... ► Artikel lesen | |
| Di | Edison Group: Edison Issues Report on Mendus (IMMU) | London, United Kingdom--(Newsfile Corp. - December 17, 2024) - Edison issues report on Mendus (OMX: IMMU)Mendus continues to make headway with its lead programme assessing cancer vaccine vididencel... ► Artikel lesen | |
| 08.11. | Mendus AB: Mendus AB Interim Report January - September 2024 | Press ReleaseStockholm, Sweden, November 8, 2024"In the third quarter of 2024, Mendus has focused on expanding the clinical development for vididencel in acute myeloid leukemia (AML) and progressing... ► Artikel lesen | |
| 27.08. | Mendus - Broad progress across the pipeline | Mendus's Q224 results reflect a period of steady progress across its clinical programmes. For vididencel, the Phase II CADENCE trial (for acute myeloid leukaemia, AML) is now ready to commence patient... ► Artikel lesen | |
| 23.08. | Mendus AB: Mendus AB Interim Report January - June 2024 | Press ReleaseStockholm, Sweden, August 23, 2024Data Reported in Q2 Confirm that Vididencel Acts as Active Immunotherapy in AMLIn the second quarter of 2024, Mendus reported in-depth immunological data... ► Artikel lesen |
